However, heterogeneity in response and survival outcomes associatedwith the current standard of care options according to Ki-67 index, morphologyand primary tumour site suggest that further investigations into the benefit oftailoring existing treatment according to these characteristics arerequired. The gene discussed is MKI67; the disease is neoplasm.